32 results about "Aspartylglutamate" patented technology

This invention relates to novel α-conotoxin-like peptides comprising the following sequence of amino acids: Xaa1CCSXaa2Xaa3Xaa4CXaa5Xaa6Xaa7Xaa8Xaa9Xaa10Xaa11C—NH2 in which Xaa1 is G or D; Xaa3 is proline, hydroxyproline or glutamine; each of Xaa2 to Xaa8 and Xaa11 is independently any amino acid; Xaa9 is proline, hydroxyproline or glutamine; Xaa10 is aspartate, glutamate or γ-carboxyglutamate; Xaa11 is optionally absent; and the C-terminus is optionally amidated, with the proviso that the peptide is not α-conotoxin Ep1 or α-conotoxin Im1. The peptides are useful in the treatment or prevention of pain, in recovery from nerve injury, and in the treatment of painful neurological conditions such as stroke.

The invention relates to a salivary gland immunoregulation polypeptide of a dieu cleg and the related genes and the application, belonging to the biomedical field. The immunoregulation polypeptide is a linear polypeptide coded with the Chinese Tabanidae salivary gland immunoregulation polypeptide genes, the sequence of which is glycin- glycin- valine- serine- glycin- valine- serine- aspartic acid- phenylalanine- glutamate- praline- isoleucine- glutamate- valine- serine- glycin- glutamate- aspartic acid- tyrosine- aspartic acid- serine- aspartic acid- glutamate- alanine- aspartic acid- glutamate- aspartic acid- glycin- lysine- alanine. The immunoregulation polypeptide gene is composed of 362 Nucleotides, wherein, the coding mature code salivary gland immunoregulation polypeptide of the dieu cleg is the 115th to the 204th nucleotide. The dieu cleg salivary gland immunoregulation polypeptide is used for inhibiting a plurality of cytokines, which is characterized by simple structure, convenient artificial synthesis and strong antibacterial activity, etc.

The invention discloses a synthetic method and an application of an antibacterial peptide. The method comprises the following steps: S1, adding a solvent and phosphoric acid into a proper amount of an amino acid raw material and roasting for 2-6 hours at 150-180 DEG C, wherein the ratio of the solvent to phosphoric acid is (3-16) to 1; and S2, taking out a dried reactant and washing by using absolute ethyl alcohol, centrifuging and airing the reactant to obtain a product antibacterial peptide, wherein the solvent is sulfolane or vegetable oil; when the solvent is sulfolane, the amino acid raw material comprises lysine or / and arginine; when the solvent is vegetable oil, the amino acid raw material comprises lysine or arginine and one or more of leucine, isoleucine, valine, phenylalanine, alanine, aspartic acid, glutamic acid, glycine, serine or threonine are added. The amino acid raw material used by the method disclosed by the invention is just lysine or / and arginine, so that the method is simple and fast and economical in synthetic cost. The synthesized antibacterial peptide has high antibacterial activity to various bacteria and can be produced and applied on a large scale.

The invention discloses an isoflavone derivative modified by acetylaminoacid benzyl ester of a general formula Ia-q, in which R1, R2 and R3 are all CH2CO-AA-OBzl or both R1 and R2 are all CH2CO-AA-OBzl, while R3 is H, wherein the AA in the CH2CO-AA-OBzl is selected from glycin, lactamine, phenyl alanine, tryptophan, isoleucine, leucine, valine, aspartic acid and glutamic acid. The invention also discloses a preparation method of the isoflavone derivative modified by the acetylaminoacid benzyl ester of the general formula Ia-q. The invention adopts an S180 mouse model to evaluate the antitumor effects of the isoflavone derivative modified by the acetylaminoacid benzyl ester of the general formula Ia-q, thus indicating that the isoflavone derivative has excellent antitumor activity and can be used as an antitumor agent.

A polypeptide calcium serving as calcium nutrition enhancer is prepared from a polypeptide intermediate obtained by copolymerizing aspartic acid or aspartic acid and glutamic acid as a raw material by reacting with edible calcium carbonate or calcium oxide (pharmaceutical grade). The polypeptide calcium contains polypeptide calcium with chemical activity, which has a molecular weight less than 1,000 and can be directly absorbed by human body, and chemical polypeptide calcium with a molecular weight of 3,000 to 5,000, which can be absorbed by human body at slower speed and has longer metabolism time. The polypeptide calcium can be sufficiently absorbed by human body, and is a green and environment-friendly calcium nutrition enhancer with wide application prospect.

An amino acid composition comprises alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and glutamine. The amino acid composition of the present invention has such an effect that it can improve the action of promoting the process wherein the body fat is converted into the energy required for the physical exercise during and / or after the anoxic motions performed under an extremely high load.

The present disclosure relates to an improved method for producing ergothioneine, comprising the steps of: (a) inoculating Pleurotus ostreatus strain CGMCC No. 6232 into a seed medium, and culturing it to prepare a seed liquor, wherein the seed medium uses soybean cake powder as nitrogen source; and (b) inoculating the seed liquor into a fermentation basal medium, and then culturing it to obtain a fermentation broth of Pleurotus ostreatus mycelia. Further, any one or more members selected from NH4Cl, NH4NO3, NaCl, polyethylene glycol, folic acid, vitamin B1 (VB1), indolebutyric acid, citric acid, pyruvic acid, arginine, lysine, leucine, aspartic acid, glutamic acid, betaine, histidine, cysteine, methionine, tween, span, chitosan, Fluconazole, Miconazole, Ketoconazole, ethylenediaminetetraacetic acid (EDTA), isopropyl alcohol and dimethyl sulfoxide are added into the fermentation basal medium.

An amino acid composition comprises alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and glutamine. The amino acid composition of the present invention has such an effect that it can improve the action of promoting the process wherein the body fat is converted into the energy required for the physical exercise during and / or after the anoxic motions performed under an extremely high load.

A pharmaceutical preparation including an amino acid infusion fluid is administered to patients receiving dialysis to ameliorate nutritional status of patients. As a result, anemia can be ameliorated and the required dose of erythropoietin can be reduced in these patients. Furthermore, the serum phosphate levels can be controlled to a predetermined range and protein catabolism can be suppressed in such patients. The amino acid infusion fluid has at least one essential amino acid. The preferred amino acid composition includes at least L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and L-cysteine, wherein the ratio of essential amino acids to non-essential amino acids is 2.5 or higher.

The invention provides a strain Alicycliphilus sp. Ylb10 which is preserved in China Center for Type Culture Collection on August 7th, 2020, the preservation number is CCTCC M 2020415, and the preservation address is Wuhan University, Wuhan, China. The strain Ylb10 is applied to restoration of Cr (VI) heavy metal pollution and reduction of Cr (VI) into Cr (III). The strain has good Cr (VI) reducing capacity, and when the concentration of environmental Cr (VI) is 50 mg / L, 96.45% of Cr (VI) is reduced within 18 hours. When the concentration of Cr (VI) in the environment is 200 mg / L, the reduction rate of Cr (VI) in 60 hours reaches 99.06%. The pH value of the optimal reduction Cr (VI) of the strain is 8-9, and the culture condition is static culture. The strain can utilize L-alanine, L-aspartic acid, L-glutamic acid, L-serine and other amino acids, and alpha-hydroxy-butyric acid, L-lactic acid, propionic acid, acetic acid and other organic acids. The Ylb10 strain is an effective hexavalent chromium reducing strain and can be applied to the field of bioremediation of chromium-polluted water samples and soil.

The invention relates to soybean paste based on pre-fermentation and using Monascus purpureus as a dominant fungus symbiotic system, and a preparation method thereof, belonging to the technical fieldof seasoning preparation. According to the invention, soybeans are used as a raw material, three-stage fermentation is performed in virtue of a composite strain composed of Monascus purpureus TYQ017,Aspergillus oryzae 3.042, Actinomucor elegans, Aspergillus niger, Penicillium, Bacillus subtilis and Kluyveromyces marxianus, so the production of free amino acids is promoted, and the contents of aspartic acid, glutamic acid and threonine are increased; through combined usage of the Bacillus subtilis, the growth of dominant fungi is promote while the production of pathogens is inhibited; and through the introduction of the Kluyveromyces marxianus, the mellow flavor of the soybean paste is improved, and the soybean paste is allowed to be bright in color, soft and smooth in mouthfeel, rich in sauce flavor and delicious and lasting in aftertaste. The soybean paste is rich in monascorubin and lovastatin while retaining the nutrition of the soybean paste, has the effects of reducing cholesterol and preventing cardiovascular diseases; and the preparation method can improve productivity and shorten a production cycle, and has good social benefits.

The invention provides a bacterial strain Alicyclophilus sp.Ylb10 was deposited in the China Center for Type Culture Collection on August 7, 2020, with the deposit number CCTCC M 2020415, and the deposit address is China.Wuhan.Wuhan University. The application of the strain Ylb10 in remediating Cr(VI) heavy metal pollution and reducing Cr(VI) to Cr(III). The strain has good Cr(VI) reduction ability. When the concentration of Cr(VI) in the environment is 50 mg / L, 96.45% of Cr(VI) can be reduced within 18 hours. When the concentration of Cr(VI) in the environment was 200 mg / L, the reduction rate of Cr(VI) reached 99.06% in 60 hours. The optimum Cr(VI) reduction pH of this strain is 8~9, and the culture condition is static culture. The strain can utilize amino acids such as L-alanine, L-aspartic acid, L-glutamic acid, and L-serine, as well as organic acids such as α-hydroxy-butyric acid, L-lactic acid, propionic acid, and acetic acid. Ylb10 bacteria is an effective hexavalent chromium-reducing bacteria, which can be applied to the bioremediation of chromium-contaminated water samples and soil.

The present disclosure relates to an improved method for producing ergothioneine, comprising the steps of: (a) inoculating Pleurotus ostreatus strain CGMCC No.6232 into a seed medium, and culturing it to prepare a seed liquor, wherein the seed medium uses soybean cake powder as nitrogen source; and (b) inoculating the seed liquor into a fermentation basal medium, and then culturing it to obtain a fermentation broth of Pleurotus ostreatus mycelia. Further, any one or more members selected from NH4Cl, NH4NO3, NaCl, polyethylene glycol, folic acid, vitamin B1 (VB1), indolebutyric acid, citric acid, pyruvic acid, arginine, lysine, leucine, aspartic acid, glutamic acid, betaine, histidine, cysteine, methionine, tween, span, chitosan, Fluconazole, Miconazole, Ketoconazole, ethylenediaminetetraacetic acid (EDTA), isopropyl alcohol and dimethyl sulfoxide are added into the fermentation basal medium.

The invention discloses a method for synthesizing a cyclic dipeptide containing aspartic acid and glutamic acid. The method uses Fmoc-Asp(OtBu)-OH or Fmoc-Glu(OtBu)-OH as raw materials, and 9- Fluorenemethanol reaction to obtain the fluorenylmethyl ester of fully protected amino acid, and then remove the side chain tert-butoxy group to obtain the protected amino acid Fmoc-Asp-OFm or Fmoc-Glu-OFm; then use 2-CTC Resin resin as the carrier and Fmoc-Asp -OFm or Fmoc-Glu-OFm side chain γ-carboxyl linkage, solid-phase cyclization to synthesize a fully protected cyclic dipeptide, cleavage and cleavage to obtain a cyclic dipeptide with aspartic acid or glutamic acid at the carbon end. The method protects the carboxyl group by introducing 9-fluorenemethanol, which can be successfully removed during the solid-phase synthesis of dipeptide. The whole process is simple to operate, high in solid-phase cyclization efficiency, and high in purity. It is suitable for batch synthesis of asparagus Cyclic dipeptides of amino acid or glutamic acid.

The invention discloses a special feed helpful for improving the meat flavor of broilers. The feed is prepared from the following components in parts by mass: 5-10% of lysine, 1-5% of methionine, 2-10% of aspartic acid, 2-10% of glutamic acid, 5-20% of sodium chloride, 20-45% of calcium hydrogen phosphate, 10-30% of stone powder, 2-7% of multivitamin, 5-15% of multi-mineral, 0.5-1.5% of antioxidant, 0.2-1% of betaine, 0.5-1.5% of phytase, 1-2.5% of choline and 0.5-1.5% of essential oil. According to the special feed helpful for improving the meat flavor of broilers, a certain amount of organictrace elements are added into the formula, so that the feed can reduce the drip loss, abdominal fat percentage and fat deposition of chicken so as to improve the tenderness of the chicken, improve the quality of the chicken and finally improve the flavor of the chicken. A certain amount of vitamin E, vitamin C and biotin are added into the feed, so that the defense capability of poultry to external diseases can be enhanced, and the production performance of the broiler chicken can be improved.

Novel nucleoside derivatives represented by the following general formula (1): wherein X is(are) the same or different and each represents a pyrimidine or purine base or a derivative thereof, Y and Y′ are the same or different and each represents at least one amino acid or amino acid derivative selected from the group consisting of serine, threonine, ornithine, aspartic acid, glutamic acid, lysine, arginine, cysteine, methionine, δ-hydroxylysine, N-aminoethylglycine, N-aminoethylserine, N-aminoethyllysine, N-aminoethylornithine, N-aminoethylaspartic acid, N-aminoethylglutamic acid, homoglutamic acid, β-thiocarbonylaspartic acid, γ-thiocarbonylglutamic acid, and δ-thiocarbonylhomoglutamic acid, R1 represents a hydrogen atom or a hydroxyl group, A represents a single bond or a carbonyl or thiocarbonyl group, 1 is an integer of 0 to 5, and n is an integer of 1 to 100.

The invention relates to polyethylene glycol derivatives of antitumor small peptides FpAT, preparation methods of the derivatives, medicinal compositions containing the derivatives, and uses of the derivatives. The polyethylene glycol derivatives of the antitumor small peptides FpAT comprise new-structure compounds obtained through modifying the N-terminal, C-terminal or the aspartic acid and glutamic acid side chains of FpAT by polyethylene glycol to prolong the half-life period of the FpAT. The polyethylene glycol derivatives of the antitumor small peptides FpAT can be used for preparing medicines for treating tumors comprising tumors of the liver cancer, the lung cancer, the stomach cancer, the colon cancer, myeloma and the like.

The invention provides a cyclic pentapeptide, the amino acid sequence of which is: cyclic-5-aspartic acid-glutamic acid-arginine-tyrosine-arginine. The cyclic pentapeptide inhibitor provided by the invention has good structural stability, can be efficiently combined with p7 channel protein, and effectively exerts the anti-hepatitis C virus effect.

The invention discloses a composite polymer colloid wound surface disinfectant containing amino acid and a preparation method of the disinfectant. The composite polymer colloid wound surface disinfectant takes polyvinylpyrrolidone and poloxamer as an emulsifier and a solubilizer, takes polyhexamethylene biguanidine, epsilon-polylysine, phenoxyethanol and water-insoluble chitosan with the degree of deacetyiation higher than 80% and the viscosity average molecular weight higher than 100,000 as bactericidal active ingredients and takes an aspartic acid, glutamic acid and cysteine mixture as a modifier and an reinforcing agent. The composite polymer colloid wound surface disinfectant is high in bactericidal capacity, high in acting speed, good in stability, safe and capable of promoting wound surface repair. The preparation method of the composite polymer colloid wound surface disinfectant comprises preparation of the chitosan solution, preparation of a polyhexamethylene biguanidine emulsion, preparation of a phenoxyethanol solution and compounding.

An extracellular vesicle separation method, a colloidal particle, and a preparation method thereof are provided. The colloidal particle is used for extracellular vesicle separation, and includes 2 wt % to 6 wt % of agarose. The colloidal particle has a particle size of 25 μm to 500 μm, and is surface-modified with biocompatible molecules. The biocompatible molecules include sodium carboxymethyl cellulose (CMC), methyl cellulose (MC), glycine, aspartic acid, glutamic acid, bovine serum albumin (BSA), fetal bovine serum (FBS), or a combination thereof.

The invention relates to preparation and application of antiglycation oligopeptide-5 (AdP), AdP is produced by adopting a genetic engineering means, the preparation comprises the following steps: carrier construction and screening, seed solution preparation, induced expression, separation and purification, etc., compared with a traditional biological peptide synthesis method, the preparation has the characteristics of small pollution, low equipment cost and simple operation, and the produced AdP is closer to natural AdP in structure, better in activity and higher in purity; and AdP is mainly prepared from alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, etc., AdP can promote generation of fibroblasts and keep skin vitality, has a good anti-aging effect, and can inhibit melanogenesis, it is found for the first time that AdP can protect macromolecular protein and effectively prevent the occurrence of protein glycosylation, and AdP has multiple effects of moisturizing, repairing, skin pigment removing and brightening, wrinkle removing and glycation resisting.

The present invention relates to novel liquid protein formulations, particularly arginine-free liquid pharmaceutical compositions of etanercept. The invention employs particular combinations and classes of buffer systems, tonicifiers, and sugar stabilisers, optionally alongside polar ionisable amino acids (e.g. aspartic acid, glutamic acid, histidine, and lysine), to afford a viable and storable drug product.

The invention belongs to the technical field of genetic engineering and enzyme engineering, and specifically relates to BmSPI39 mutant and application thereof. BmSPI39 is composed of the 25th to 98th positions in SEQ ID NO.1. The BmSPI39 mutant is the amino acid sequence of BmSPI39, as shown in SEQ ID NO.1, the alanine at the 56th position is mutated to arginine, Lysine, Serine, Threonine, Glutamine, Tyrosine, Methionine, Leucine, Aspartic Acid, Glutamic Acid, Histidine, Cysteine, Valine, Astragalus Paragine, Isoleucine, Phenylalanine, Tryptophan, Proline or Glycine. The BmSPI39 mutants of the present invention all have inhibitory activity on subtilisin and elastase, and when mutated to arginine or lysine, they also obtain trypsin inhibitory activity, and such mutants can be used to prepare trypsin inhibitors , the application prospect is good.

The document relates to a composition comprising Docetaxel, human serum albumin, and one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1. The document also relates to a composition comprising Docetaxel, human serum albumin, one or more amino acids selectedfrom aspartic acid, glutamic acid, and cysteine, and a sugar alcohol or a sugar, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1.

An infusion preparation which is to be used in dialyzing a dialysis patient for ameliorating the anemic state by improving nutritional conditions, thus reducing the dosing amount of erythropoietin, controlling the serum phosphorus level to thereby regulate the serum phosphorus level within a definite range and inhibiting the protein catabolism and which contains at least essential amino acids, characterized in that the amino acids are composed of at least L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and L-cysteine and the ratio of essential amino acids : non-essential amino acids is 2.5 or higher.

The invention discloses a submerged fermentation phellinus linteus mycelium glycoprotein, a usage and a separation extraction preparation method thereof, the complex is the complex of heteropolysaccharide and protein, wherein, the content of the heteropolysaccharide is 15 to 20 percent, and the heteropolysaccharide is composed of three monosaccharides of glucose monosaccharide, xylose and mannose; the content of the protein is 80 to 85 percent, and the protein is composed of 18 amino acids of aspartic acid, glutamic acid, arginine and so on; and the weight-average molecular weight is 20 to 40KD. The glycoprotein complex uses bran extract liquid as a main ingredient for preparing a culture medium, the phellinus linteus mycelium is produced by the submerged fermentation of the phellinus linteus bacterial strain liquid, the homogenization, the cold-water extraction, the centrifugalization, the collection of supernatant liquid, the precipitation of ammonium sulfate, the dialysis and the DEAE-Sepharose Fast Flow column chromatography are carried out for system separating and purifying the glycoprotein complex. The anti-bacterial glycoprotein is used for preparing the anti-bacterial dugs which have inhibitory effects on escherichia coil and staphylococcus aureus. At the same time, the glycoprotein complex can be used for the separation and the purification of the glycoprotein from the mycelium obtained by the submerged fermentation of various medical and edible fungi.

The invention discloses a method for simultaneously determining five amino acid neurotransmitters in a biological matrix based on a two-dimensional liquid chromatography-ultraviolet derivatization method, which comprises the following steps: carrying out pre-column derivatization pretreatment on a biological sample to obtain a solution to be detected, detecting the solution to be detected through a two-dimensional liquid chromatography system, and quantitatively analyzing five amino acid neurotransmitter targets. The method realizes simultaneous and rapid detection of multiple components by two-dimensional liquid chromatography, has the advantages of large sample introduction volume, high resolution, good peak shape, no influence by other endogenous amines and the like, and is suitable for qualitative and quantitative detection of aspartic acid, glutamic acid, glycine, taurine and gamma-aminobutyric acid in endogenous biological samples.

The invention discloses a synthetic method of cyclic dipeptide containing aspartic acid and glutamic acid, which comprises the following steps: by taking Fmoc-Asp (OtBu)-OH or Fmoc-Glu (OtBu)-OH as a raw material, reacting with 9-fluorene methanol to obtain fluorene methyl ester of fully protected amino acid, and then removing side chain tert-butoxy to obtain protected amino acid Fmoc-Asp-OFm or Fmoc-Glu-OFm; 2-CTC Resin resin is used as a carrier to be bonded with Fmoc-Asp-OFm or Fmoc-Glu-OFm side chain gamma-carboxyl, solid-phase cyclization is carried out to synthesize full-protection cyclic dipeptide, and the cyclic dipeptide with aspartic acid or glutamic acid at the carbon end is obtained through cutting and cracking. According to the method, 9-fluorene methanol is introduced to protect carboxyl, the carboxyl can be smoothly removed in the solid-phase synthesis process of the dipeptide, the whole process is easy to operate, the solid-phase cyclization efficiency is high, the purity is high, and the method can be suitable for batch synthesis of cyclic dipeptide with aspartic acid or glutamic acid at the carbon end.

A polypeptide cleavage method characterized in that arginine or lysine is at the P1 position of a desired cleavage site in a polypeptide, an amino acid other than aspartic acid, glutamic acid or proline is at the P1′ position, a single basic amino acid or two or three consecutive basic amino acids are situated at any site in the amino acid sequence from the P10 position to the P3 position or from the P3′ position to the P5′ position (with the proviso that a single basic amino acid is not situated at the P6 or P4 position), and OmpT protease or its variant enzyme having a substitution at the 97th amino acid from the N-terminus is used to cleave the desired cleavage site in the polypeptide.

The invention belongs to the technical field of gene engineering and enzyme engineering, and particularly relates to a BmSPI39 mutant and application thereof. The BmSPI39 is composed of the 25th site to the 98th site in SEQ ID NO.1. The BmSPI39 mutant is obtained by synthesizing a BmSPI39 amino acid sequence into a BmSPI39 amino acid sequence, a BmSPI39 amino acid sequence and a BmSPI39 amino acid sequence. The amino acid mutant is obtained by mutating the 56th alanine as shown in SEQ ID NO.1 into arginine, lysine, serine, threonine, glutamine, tyrosine, methionine, leucine, aspartic acid, glutamic acid, histidine, cysteine, valine, asparagine, isoleucine, phenylalanine, tryptophan, proline or glycine. The amino acid mutant is obtained by mutating the 56th alanine as shown in SEQ ID NO.1 into arginine, lysine, serine, threonine, glutamine, tyrosine, methionine, leucine, aspartate, glutamic acid, histidine, cysteine, valine, asparagine, isoleucine, phenylalanine, tryptophan, proline or glycine. The BmSPI39 mutant disclosed by the invention has inhibitory activity on subtilisin and elastase, trypsin inhibitory activity is also obtained when the BmSPI39 mutant is mutated into arginine or lysine, and the mutant can be used for preparing a trypsin inhibitor and has a good application prospect.